Study to Assess the PK Profile of NanoBUP Capsules Relative to Suboxone

NCT01260675 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 12

Last updated 2017-06-23

No results posted yet for this study

Summary

Phase 1 study to determine the pharmacokinetic profile of NanoBUP Capsules to Suboxone.

Conditions

  • Healthy

Interventions

DRUG

Buprenorphine HCl/Naloxone HCl

Sponsors & Collaborators

  • NanoSHIFT LLC

    lead INDUSTRY

Principal Investigators

  • Michael Natalino, MD · Worldwide Clinical Trials

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2010-12-31
Primary Completion
2011-01-31
Completion
2011-01-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01260675 on ClinicalTrials.gov